Novo Nordisk v. Hims and Hers: the compounded GLP-1 case
In February 2026, Novo Nordisk filed suit against Hims & Hers over its compounded GLP-1 marketing. The case turns on a specific — and genuinely unsettled — legal question about compounding law.
TL;DR
- Novo Nordisk filed suit against Hims & Hers in February 2026, alleging that Hims’s marketing of compounded GLP-1 products implied FDA approval of products that were not approved.
- The central legal question is whether certain compounded GLP-1 formulations constitute “essentially a copy” of an approved drug under Section 503A of the FDCA — and therefore fall outside legal compounding eligibility.
- The case is pending as of publication date. It has significant implications for how compounded GLP-1 can be marketed across the telehealth industry.
What it is
This is active civil litigation filed in the United States District Court. Novo Nordisk A/S, the manufacturer of Ozempic and Wegovy (semaglutide), filed suit against Hims & Hers Health, Inc. in February 2026. The complaint, as reported by multiple legal and trade publications, alleged that Hims’s marketing of compounded semaglutide formulations misrepresented the products’ regulatory status and, in some versions of the claims, implied a relationship or similarity to Novo Nordisk’s branded products that Novo Nordisk contends was misleading. The case is pending in federal court and has not reached a verdict or settlement as of the date of this article.
How it works
The legal framework at the center of this case is Section 503A of the Federal Food, Drug, and Cosmetic Act, which governs traditional compounding by state-licensed pharmacies. Under 503A, compounded medications cannot be “essentially a copy” of a commercially available FDA-approved drug — unless a prescribing clinician determines that the commercially available version does not meet a patient’s specific needs. The “essentially a copy” prohibition is intended to prevent compounding from becoming a workaround for FDA drug approval requirements.
The legal dispute centers on whether compounded semaglutide formulations — even when they are prepared from bulk active pharmaceutical ingredients by licensed 503A pharmacies — cross the line into being “essentially a copy” of Wegovy or Ozempic. This is a genuinely unsettled area of law; courts and the FDA itself have not established a bright-line standard that answers the question definitively in all contexts. The litigation is one of several concurrent mechanisms — including FDA enforcement letters and Congressional scrutiny — through which this legal boundary is being actively tested.
Who asks about it
People come to this topic when they have seen news coverage of the Hims lawsuit and want to understand what it means for their own access to compounded GLP-1 products. It’s also a question that informed healthcare consumers and clinicians ask because the case’s outcome could affect the operational and legal landscape for compounded GLP-1 access more broadly.
What the research says
There is no peer-reviewed research on this specific litigation — it is a legal development, not a clinical one. The relevant published law is the text of Section 503A of the FDCA and the FDA’s associated guidance documents, which are available at FDA.gov. The specific prohibition on “essentially a copy” compounds is described in FDA guidance titled “Caveats to the Exemptions Under Section 503A” published in 2018. Trade publications including STAT News, MedCity News, and The Wall Street Journal have covered the filing and its implications in detail.
What to know before considering it
Compounded GLP-1 products are the subject of ongoing litigation (Novo Nordisk v. Hims & Hers, Feb. 2026). The regulatory and legal landscape for these products continues to evolve. Patients and clinicians should be aware that the legal parameters around compounded GLP-1 marketing and eligibility are actively being tested in court. Any platform providing compounded GLP-1 should be operating under the guidance of legal counsel familiar with current 503A requirements.
The Halftime POV
This case is worth following because it will help define — either through judgment or settlement — what “essentially a copy” means in practice for compounded GLP-1. That matters to anyone building or using a telehealth model in this space. What it underscores for us is the importance of operating on a compliance-first foundation: precise language, accurate disclosures, and no marketing that overstates what a compounded product is or isn’t.
Related reading:
FAQ
Q: What is the Novo Nordisk v. Hims and Hers lawsuit about? A: Novo Nordisk filed suit in February 2026 alleging that Hims & Hers marketed compounded semaglutide in ways that infringed on Ozempic/Wegovy branding and misled consumers about the nature of compounded products. The core legal question is whether compounded semaglutide marketing created consumer confusion with FDA-approved branded products — a Lanham Act issue.
Q: How does this litigation affect compounded GLP-1 access? A: Pending litigation does not immediately change the regulatory status of compounded GLP-1. 503A pharmacies can continue to compound semaglutide and tirzepatide for patients with valid prescriptions from licensed clinicians, provided they comply with current FDA guidance on shortage status and marketing language. The lawsuit’s outcome could affect marketing practices, not compounding legality per se.
Q: What should patients know about compounded GLP-1 and this litigation? A: Compounded GLP-1 medications are legally distinct from branded products like Ozempic or Wegovy — they are patient-specific preparations, not generic equivalents. The litigation targets marketing practices that blurred this distinction. Patients receiving compounded GLP-1 from a licensed clinician through a 503A pharmacy are operating within the legal framework as it stands.
Disclaimer
This article is educational and is not medical advice. Compounded GLP-1 medications are prepared by state-licensed 503A compounding pharmacies from FDA-approved active pharmaceutical ingredients and are not themselves FDA-approved. GLP-1 therapies are available only with a valid prescription following a licensed clinician evaluation. Clinical outcomes depend on individual factors including baseline health, adherence, diet, and physical activity. Individual results vary. Side effects are common and may include nausea, injection-site reactions, and gastrointestinal symptoms. Halftime Health is launching soon — join the waitlist to get updates.
Note on ongoing litigation: Compounded GLP-1 products are the subject of ongoing litigation (Novo Nordisk v. Hims & Hers, Feb. 2026). The regulatory landscape for compounded GLP-1 formulations continues to evolve.
Get updates
Halftime Health is launching soon. We’ll share what we learn along the way — the research, the regulations, the real-world trade-offs. Join the waitlist and we’ll email you when we’re live.
Sources
- FDA. “Section 503A of the Federal Food, Drug, and Cosmetic Act.” FDA.gov
- FDA. “Caveats to the Exemptions Under Section 503A.” FDA Guidance Document, 2018
- STAT News. Coverage of Novo Nordisk v. Hims & Hers litigation, February 2026
- MedCity News. “Novo Nordisk sues Hims & Hers over compounded semaglutide marketing.” February 2026
